[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-impairment-mild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-impairment-mild":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,113,138,168,196,228,249,278,317,345,376,408,436,458,482],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053556","cognitive-care-bundle-for-ischaemic-stroke--a-pilot-randomised-controlled-trial-100053556",false,"NCT07610291","Cognitive Care Bundle for Ischaemic Stroke : A Pilot Randomised Controlled Trial","Application of Cognitive Care Bundle to Ischaemic Stroke Patients and Its Effect on Post-Stroke Cognitive Outcome: A Pilot Randomised Controlled Trial","COGIS","Inclusion Criteria:\n\n1. Age 18 years old or older\n2. Diagnosis of ischemic stroke within 7 days\n3. Mild cognitive impairment noted during admission of stroke (MoCA 18-25)\n\nExclusion Criteria:\n\n1. GCS \\\u003C8\n2. Pre-stroke neurodegenerative disease (Parkinson's, Alzheimer's, Vascular Dementia, Frontotemporal Dementia, Mixed Dementia, Lewy Body Dementia)\n3. Patient with previous stroke\n4. Modified Rankin Scale of 4 and above\n5. Known psychiatric disorder\n6. Patient on psychotherapy medications (benzodiazepine, antidepressant, etc)\n7. Severe aphasia\n8. Logistical issues hindering follow up\n9. Delirium","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a set of treatments, called a \"cognitive care bundle,\" can help preserve cognitive ability in people who have had a stroke. This study will also test how feasible it is for people to follow this care bundle.\n\nThe main questions it aims to answer are:\n\n1. Do people find it feasible to follow the care bundle, which includes daily home blood pressure checks (and blood sugar checks for those with diabetes), along with referrals to specialists like dietitians, eye doctors, hearing specialists, and mental health professionals?\n2. Do people who receive the cognitive care bundle have better cognitive scores 3 months after their stroke, compared to those who receive standard care?\n\nResearchers will compare two groups of stroke survivors. One group will receive the cognitive care bundle plus standard medical care. The other group will receive standard medical care alone. This comparison will help researchers see if the care bundle works better to prevent cognitive decline.\n\nParticipants in the intervention (care bundle) group will:\n\nCheck and record their blood pressure daily at home (and their blood sugar too, if they have diabetes). Talk with a doctor weekly over the phone to review their readings and adjust medications if needed\n\nSee a dietitian for a personalized eating plan\n\nHave a hearing test by an audiologist\n\nHave a basic vision test by the research team\n\nAnswer a short questionnaire about their mood to screen for depression\n\nAll participants (in both groups) will undergo physiotherapy and cognitive training. Participants will be followed up with blood tests, examination by a doctor and questionnaires after 3 months.\n\nThis is a pilot study to see if this approach works and is practical to do in a larger future study.",[27,28],"Ischaemic Stroke","Cognitive Impairment, Mild",[30,31,32,33,34,35,36],"post-stroke cognitive impairment","care bundle","pilot","intervention","cognitive rehabilitation","blood pressure","hyperglycaemia","NOT_YET_RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2029-04",{"name":47,"class":48},"National University of Malaysia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":92,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":49},"100454745","interventions-in-mathematics-and-cognitive-skills-100454745","NCT05201534","Interventions in Mathematics and Cognitive Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scle of Intelligence (WASI-II).\n3. Identification of Mathematical Learning Disabilities: Scores below the 35th percentile percentile on symbolic number processing test in Numeracy Screener and two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 35th percentile percentile on symbolic number processing test in Numeracy Screener and all WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder.)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, claustrophobia)",true,"6 Years","12 Years",{"count":61,"type":21},180,[24],"The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).",[65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,28,86,87,88,89,90,91],"Math Learning Disability","Child Development","Developmental Disability","Learning Disabilities","Learning Disabled","Learning Curve","Mathematics Disorder","Dyscalculia","Dyscalculia, Primary","Dyscalculia, Acquired","Specific Learning Disorder, With Impairment in Mathematics","Individuality","Behavior, Child","Behavior and Behavior Mechanisms","Behavior","Decision Making","Neuronal Plasticity","Cognition","Cognition Disorder","Cognitive Dysfunction","Cognitive Change","Cognitive Developmental Delay","Cognitive Orientation","Cognitive Delay, Mild","Cognitive Deficits, Mild","Cognitive Abnormality","Neuroscience",[93,94,95,96,97,98,99,100,101,102],"Numerical skills in children","Low math abilities","Mathematical Learning Disabilities","Mathematical Concepts","Mathematics","Transfer, Psychology","Generalization, Psychology","Early Intervention, Educational","Neural Pathways","Neural Networks, Computer","RECRUITING","2026-06-22",{"date":106,"type":41},"2026-06-25",{"date":108,"type":41},"2023-05-05",{"date":110,"type":21},"2026-08-31",{"name":112,"class":48},"Stanford University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":49},"100641153","modifiable-risk-factors-for-cognitive-dysfunction-in-patients-with-coronary-heart-disease-100641153","NCT07657624","Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease","Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of coronary heart disease (meeting at least one of the following):\n\n   * Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;\n   * Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;\n   * Objective evidence of myocardial ischemia or typical clinical symptoms\n3. Completion of standardized neuropsychological assessment during hospitalization\n4. Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments\n5. Provision of signed written informed consent\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia.\n2. History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.\n3. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n4. Pregnancy or breastfeeding.",{"count":121,"type":21},2352,"OBSERVATIONAL","This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.",[125,28],"Coronary Heart Disease",[127,128,125],"Risk Factors","Cognitive Impairment","2026-06-15",{"date":131,"type":41},"2026-06-18",{"date":133,"type":21},"2026-06-30",{"date":135,"type":21},"2031-05-01",{"name":137,"class":48},"Beijing Anzhen Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":57,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100382636","phase-4-pragmatic-evaluation-of-events-and-benefits-of-lipid-lowering-in-older-adults-100382636","NCT04262206","Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults","PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)","PREVENTABLE","Inclusion Criteria:\n\n* Community-dwelling adults\n* Age ≥75 years\n* English or Spanish as primary language\n* Able to provide a trusted contact\n\nExclusion Criteria:\n\n* Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)\n* Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)\n* Dementia (clinically evident or previously diagnosed)\n* Dependence in any Katz Basic Activities of Daily Living \\[ADL\\] (with the exception of urinary or bowel continence)\n* Severe hearing impairment (preventing phone follow up)\n* Unable to talk (preventing phone follow up)\n* Statin use in the past year or for longer than 5 years previously (participant reported)\n* Ineligible to take atorvastatin 40 mg (clinician determined)\n* Documented intolerance to statins\n* Active Liver Disease","75 Years",{"count":148,"type":21},20000,[150],"PHASE4","PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.",[28,153,154],"Dementia","Cardiovascular Diseases",[156,157],"statin","older adults","2026-06-02",{"date":160,"type":41},"2026-06-04",{"date":162,"type":41},"2020-09-01",{"date":164,"type":21},"2026-12-31",{"name":166,"class":48},"Duke University",103,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":49},"100638943","how-video-game-therapy-affects-thinking-and-emotions-in-older-adults-with-cognitive-impairment-100638943","NCT07615647","How Video Game Therapy Affects Thinking and Emotions in Older Adults With Cognitive Impairment","COGNITIVE AND AFFECTIVE-MOTIVATIONAL EFFECTS OF A THERAPEUTIC INTERVENTION USING THE GOLDEN GAMERS METHODOLOGY IN OLDER ADULTS WITH COGNITIVE IMPAIRMENT","Inclusion Criteria:\n\n* Older adults with mild to moderate cognitive impairment, able to connect with their environment and participate in group or individual activities, and who agree to take part in the study.\n\nExclusion Criteria:\n\n* Severe cognitive impairment with lack of environmental awareness, serious visual limitations that prevent interaction, or any condition causing distress or making participation unsafe.","65 Years",{"count":177,"type":21},60,[24],"Golden Gamers Go is running a study together with Rey Juan Carlos University to better understand how videogames can help older adults, especially those with memory problems or cognitive decline.\n\nThe study takes place in real care settings, such as day centers, and involves around 45 older participants. Over two months (with a possible follow-up period), participants take part in two to three sessions per week using video games on PlayStation.\n\nThese are not special \"health games,\" but popular, commercial video games that have been carefully selected and adapted to be easy to use, enjoyable, and meaningful for older adults.\n\nThe goal is to see whether playing these games can help improve thinking abilities and also how participants feel during the activity - for example, if they are more engaged, motivated, or emotionally positive.\n\nThis study builds on previous experience where this approach has already shown promising results in increasing participation, motivation, and overall wellbeing.\n\nBy carrying out this research, Golden Gamers Go aim to better understand how meaningful and enjoyable activities like videogames can support healthier and more active aging.",[181,28],"Older Adults (65 Years and Older)",[183,184,185,186],"Alzheimer","Senior","Videogames","Therapy","2026-05-28",{"date":189,"type":41},"2026-05-29",{"date":191,"type":41},"2026-04-13",{"date":193,"type":21},"2026-07-06",{"name":195,"class":48},"Golden Gamers Go SL",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":57,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":49},"100629097","cognitive-assessment-and-post-operative-complications-after-surgery-linking-anaesthesia-and-risk-100629097","NCT07470216","Cognitive Assessment And Post-Operative Complications After Surgery: Linking Anaesthesia And Risk","CAPSULAR","Inclusion Criteria:\n\n* Age ≥ 70\n* Seen in the Perioperative medicine for Older People undergoing Surgery (POPS) clinic\n* Scheduled for colorectal or urological surgery with expected anaesthesia time over 60 minutes\n\nExclusion Criteria:\n\n* Regional anaesthesia only\n* Planned day surgery or expected hospital stay \\\u003C 24 hours\n* Expected to remain sedated and ventilated for \\> 24 hours postoperatively\n* Participant does not wish to remain in the study if capacity is lost during the study\n\nCO-ENROLMENT\n\n* As this is a non-intervention study, co-enrolment will be permitted in other studies that do not conflict with this protocol.","70 Years",{"count":205,"type":21},40,"Many older people can experience confusion, memory problems, or a decline in their thinking after major surgery. These problems are sometimes called 'postoperative neurocognitive disorders' or PND and can affect recovery and a person's ability to live independently.\n\nThe investigators want to find out the best way to study these problems in older patients undergoing surgery. This is a 'feasibility study', which means we are testing the research methods. The investigators want to see if it is possible to ask participants to do memory tests and give blood samples before and after their operation. The investigators are hoping to include around 40 patients over 2 years in this study.\n\nThe investigators will compare performance in memory (cognitive assessment) findings before and after surgery and link this to data taken from the anaesthetic, including the types of drugs used, duration, brain features from processed electroencephalogram monitoring and standard recommended monitoring. In addition the investigators will link this to blood sample markers of brain health and function (biomarkers).\n\nThe results of this study will help the investigators plan a much larger study in the future, with the ultimate goal of making surgery safer for the brain.",[128,28,208,209,210,211],"Cognitive Impairment, Progressive","Anesthesia","Anesthesia Brain Monitoring","Anesthesia Depth Monitoring",[213,214,215,216,217,218],"cognitive impairment","cognitive impairment, mild","cognitive impairment, progressive","anesthesia","anesthesia brain monitoring","anesthesia depth monitoring","2026-05-04",{"date":221,"type":41},"2026-05-08",{"date":223,"type":21},"2026-07-01",{"date":225,"type":21},"2028-03",{"name":227,"class":48},"University of Edinburgh",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":49},"100601077","dance-intervention-to-improve-executive-function-and-physical-performance-in-older-adults-with-cognitive-impairment-100601077","NCT07105800","Dance Intervention to Improve Executive Function and Physical Performance in Older Adults With Cognitive Impairment","A Pilot Study of Dance Intervention for Enhancing Executive Function and Physical Performance in Cognitively Impaired Older Adults","Inclusion Criteria:\n\n* Subjective Cognitive Decline (SCD) with a score ≥5 on the SCD-Q9 questionnaire, or Mild Behavioral Impairment (MBI) with a score ≥7 on the MBI-Checklist, with symptoms persisting for more than three months.\n* Ability to follow instructions.\n* Ability to stand unsupported or with assistive devices for at least 10 minutes.\n* Ability to walk at least 10 meters, either unsupported or with assistive devices.\n\nExclusion Criteria:-Age below 55 years.\n\n* Severe visual or hearing impairment.\n* Score \\\u003C16 on the Montreal Cognitive Assessment (MoCA).\n* Emotional or anxiety symptoms caused by psychiatric medications that significantly impair the ability to perform study-related motor tasks.","55 Years",{"count":20,"type":21},[24],"This pilot study investigates the effects of a music-based dance intervention on executive function and physical performance in middle-aged and older adults with cognitive impairment. Dance, as a form of dual-task training, integrates music, rhythmic movement, and cognitive-motor coordination. When combined with group interaction and partner-guided physical cues, it has the potential to enhance both cognitive and motor functions simultaneously.\n\nThe intervention features a simple, structured dance sequence designed to stimulate rhythm, attention, and coordination through music-based movement. This study aims to evaluate the feasibility and preliminary efficacy of this approach in improving executive function and lower limb physical performance among individuals with cognitive impairment.",[240,28],"Older Adults","2026-04-27",{"date":243,"type":41},"2026-04-28",{"date":245,"type":41},"2025-11-01",{"date":133,"type":21},{"name":248,"class":48},"Taipei Medical University Shuang Ho Hospital",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":146,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":49},"100610496","early-phase-1-cholinergic-enhancement-of-theta-100610496","NCT07228338","Cholinergic Enhancement of Theta","Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity","Inclusion Criteria:\n\n1. Age 18 - 75 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n\nExclusion Criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.\n3. Hepatic impairment (moderate or severe).\n4. Renal impairment (moderate or severe).\n5. Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.\n6. History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).\n7. Untreated narrow-angle glaucoma.\n8. Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).\n9. Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.\n10. Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.\n11. Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.\n12. Drugs Eliminated by Active Tubular Secretion.\n13. Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.",{"count":20,"type":21},[258],"EARLY_PHASE1","The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and\u002For associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.",[261,262,28,263,264],"Epilepsy","Seizures","Memory Disorder","Memory Loss",[266,267,268],"oscillatory changest","cholinergic agonist","muscarinic agonist","2026-04-08",{"date":271,"type":41},"2026-04-09",{"date":273,"type":21},"2026-10",{"date":275,"type":21},"2031-10",{"name":277,"class":48},"University of Texas Southwestern Medical Center",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":295,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":49},"100567542","effects-of-real-vs-soundless-acoustic-stimulation-during-deep-sleep-on-brain-activity-memory-and-blood-biomarkers-in-older-adults-60-85-with-mild-memory-impairment-100567542","NCT06669546","Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment","Preventing Cognitive Decline Using Portable, Non-invasive Sleep Enhancement","Inclusion Criteria:\n\n* Written informed consent\n* Age between 60 and 85 years\n* Cognitive impairment (subjective and\u002For MoCA between 23-26)\n* Native German speakers or comparably fluent\n* Normal or corrected-to-normal vision.\n* Intact hearing\n* A close cohabitant (partner\u002Fsibling) should be present to support participants in using study materials\u002Fdevices.\n\nExclusion Criteria:\n\n* Insomnia assessed by the Regensburg Insomnia Scale (RIS; Crönlein et al., 2013)\n* Restless leg syndrome assessed by questions concerning typical symptoms.\n* Sleep apnoea assessed by the Berlin Questionnaire (BQ; Netzer et al., 1999)\n* Severely irregular sleep patterns assessed by the RIS and the Pittsburgh sleep quality index (PSQI; Buysse et al., 1989)\n* Symptoms of depression (Geriatric Depression Scale (GDS; Yesavage et al., 1982) ≥ 5)\n* History of untreated severe neurological and psychiatric diseases\n* Alcohol or substance abuse\n* Use of medication acting on the central nervous system","60 Years","85 Years",{"count":177,"type":21},[24],"This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS is important for memory and clearing waste from the brain. Poor SWS can worsen memory loss and allow harmful waste to build up, which may increase the risk of dementia.\n\nThe investigators are testing whether phase-locked auditory stimulation (PLAS) can improve SWS in people at a mild stage of cognitive impairment. PLAS uses short sounds played at specific moments to strengthen slow-wave brain activity during sleep. The investigators previous laboratory based research has shown that this can improve memory and help with clearing waste from the brain. Now, the investigators want to test this in a real-world setting, over a longer period, which is unfeasible in a laboratory setting.\n\nIn this study, 60 older adults will use home-use devices that deliver either real or sham (soundless) PLAS across two different 4-week periods. Memory will be tested using engaging \"serious games.\" Before and after each experimental period, blood samples will be taken to measure dementia-related markers, and cognitive batteries will be performed. The investigators expect that PLAS will improve sleep, and that this will have a downstream effect on memory and brain clearance, potentially slowing the process of cognitive decline.\n\nIf successful, this could lead to the development of an affordable treatment that helps people maintain brain health and prevent dementia.",[291,292,293,294,28],"Cognitive Decline","Alzheimer Disease","Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)",[296,153,297,298,299,300,301,302,303,304,82,305,306,307],"Sleep","Prevention","Phase-locked auditory stimulation","Blood-based biomarkers","Home","Longitudinal","Electroneurophysiology","EEG","Memory","Serious games","Old age","Human","2026-04-02",{"date":310,"type":41},"2026-04-03",{"date":312,"type":41},"2025-02-21",{"date":314,"type":21},"2028-12",{"name":316,"class":48},"University of Bern",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":49},"100560973","buddy-up-dyadic-physical-activity-program-for-persons-with-dementia-and-family-caregivers-100560973","NCT06584110","Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers","Effects of Buddy-Up Dyadic Physical Activity Program on Health Outcomes and Social Dynamic of Persons With Dementia and Family Caregivers: A Mixed Method Randomized Controlled Trial","BUDPA","Eligibility for person with dementia (PwD) includes i) a confirmed diagnosis of dementia and ii) an HK-MoCA score of 8-19 to indicate mild to early moderate dementia.\n\nThe caregivers will have to i) live with the participant with dementia ii) self-identify as the primary family caregiver iii) providing care for ≥ 4 hours\u002Fday iv) has a smartphone for FaceTime\n\nThe exclusion criteria are i) engaging in ≥60 min\u002Fweek of moderate or vigorous exercise in the past six months ii) having acute muscular-skeletal problems, cerebro-cardio-respiratory disease or condition contradictory to exercise training",{"count":326,"type":21},236,[24],"The global cost of dementia is over 818 billion, and a further rise is expected in the next decade. While family caregiving is the backbone of the formal care service, promoting \"living well with dementia\" needs to extend to a dyadic perspective to address the needs of persons with dementia (PwD) and their caregivers. Unique to dementia caregiving, imbalanced exchange in the assistance, interaction, relationship and autonomy between the partners in a care dyad always challenges their social interaction and relationships. Such eroding dyadic dynamics not only worsens the mental health of caregivers, but also compromises the quality of caregiving, fosters more dementia deterioration, and eventually complicates the caregiving process. Nevertheless, least attention is directed to dyadic dynamics in promoting living well with dementia. Partner exercise is designed in a way which requires collaboration of two members to enable the workout of each other. In addition to the benefits of exercise on dementia symptom control and caregiver's stress management, partner exercise provides a meaningful encounter to encourage reciprocity, collaboration and relationship closeness within the care dyad.\n\nThis is a sequential mixed-method study including a multicenter RCT to evaluate the effects of the 16-week enhanced BUDPA and a descriptive qualitative study to explore the care dyad's overall engagement experience and perceptions. The study will be conducted in 8 elderly community centres operated by four NGOs.\n\nThe primary aim of the study investigates the effects of a 16-week enhanced BUDPA program on the health and dyadic dynamic of the persons with dementia and their family caregivers (Objective 1-3). The secondary aim explores dyads' overall experience in program engagement, particularly in terms of perceived benefits, challenges, and experience in self-directed practice (Objective 4). The primary outcomes include PwD's cognitive function and caregivers' mood status.\n\nWe hypothesize that the 16-week enhanced BUDPA program will be more effective than usual care immediately post-test (T1: week 16) and 3 months (T2: week 29) and 6 months thereafter (T3: week 42) in:\n\n1. improving cognitive function, NPS and HRQL of persons with mild to early-moderate dementia.\n2. improving the affect, positive aspects of caregiving, and HRQL of family caregivers.\n3. improving the dyadic dynamic between the person with dementia and family caregiver in a dyad.",[28,330,153,331],"Dementia, Mild","Caregiver Burden",[333,334,213,335],"dementia","dyads exercise","caregiver","2026-03-31",{"date":338,"type":41},"2026-04-06",{"date":340,"type":41},"2024-10-01",{"date":342,"type":21},"2027-03-30",{"name":344,"class":48},"The University of Hong Kong",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":285,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":354,"conditions":355,"keywords":360,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":375},"100611163","effects-of-personalized-digital-reminiscence-therapy-on-patients-with-neurocognitive-disorders-100611163","NCT07237009","Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders","Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders","Inclusion Criteria:\n\n* Men and women over 60 years of age.\n* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.\n* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.\n* Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both\n* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.\n* Having voluntarily and informedly agreed to participate in the study (signed written consent).\n* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).\n* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.\n* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.\n* Subjects covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.\n* Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).\n* Major hearing or visual impairments.\n* History of premorbid intellectual disability.\n* Patients under guardianship, conservatorship, or legal protection.\n* Patients who have already used the Lilia app\n* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.\n* Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.",{"count":353,"type":21},80,"This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.\n\nThe researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.\n\nThe study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.\n\nParticipants will:\n\n* Use the reminiscence app for 25 days for 10-15 minutes.\n* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.\n* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).",[356,28,357,358,359],"Neurocognitive Disorders, Mild","Depression Mild","Apathy","Apathy in Dementia",[361,153,358,362,363,364],"Mild Cognitive Impairment","Mild Depression","Digital Reminiscence therapy","personalized Reminiscence therapy","2026-03-06",{"date":367,"type":41},"2026-03-09",{"date":369,"type":41},"2025-10-14",{"date":371,"type":21},"2026-12",{"name":373,"class":374},"KompanionCare SAS","INDUSTRY",5,{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":17,"minAge":384,"maxAge":286,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":389,"conditions":390,"keywords":393,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":49},"100565215","phase-2-repurposing-siponimod-for-alzheimers-disease-100565215","NCT06639282","Repurposing Siponimod for Alzheimer's Disease","SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease","SIPO1-AD","Inclusion Criteria:\n\n1. Male or female at least 50 years of age, but less than 85 (84 at time of screening)\n2. Females must be of non-childbearing potential or have negative pregnancy test at time of screening. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for \\>12 months prior to the planned date of enrollment.\n3. Must have a diagnosis of mild Alzheimer's Dementia determined by medical record review.\n4. Vision and hearing must be sufficient to comply with study procedures.\n5. Be able to take oral medications.\n6. Must be able to attend all study visits indicated in the schedule of visits.\n7. Must have a collateral informant\u002Fstudy partner who has significant direct contact with the patient at least 10 hours per week and who is willing to accompany the patient to specified clinic visits, supervise administration of all study medication, and be available for telephone visits\u002Finterviews.\n8. Documented Mini Mental State Exam (MMSE) score between 20-26 at Screening Visit Day 1.\n9. CT or MRI scan of the brain within 12 months of Screening Visit Day 1 showing no evidence of significant focal lesions or other pathology which could contribute to dementia. If neither a CT or a MRI scan is available from the past 12 months, a scan fulfilling the requirements must be obtained before randomization.\n10. Hachinski ischemic score must be \\\u003C 4.\n11. Geriatric depression scale must be \\\u003C 10.\n12. Prior to dosing all randomized study subjects must show proof they have received immunization to varicella (VZV IgG).\n13. Each patient must be assessed for capacity to consent by the principal or sub-investigators in order to provide informed consent. If the patient is deemed unable to provide informed consent, they must have a legally authorized representative (LAR), and the LAR must review and sign the informed consent form. If the patient does not have a LAR, the patient must appear able to provide informed consent and must review and sign the informed consent form. If the patient is deemed unable to provide informed consent and does not have a LAR, they cannot participate in the study. In addition, the patient's study partner\u002Finformant (as defined in the study inclusion criteria) must sign the informed consent form. If the LAR and the patient's study partner\u002Finformant are the same individual, he\u002Fshe should sign under both.\n14. No active suicidality identified on Columbia-Suicide Severity Rating Scale (C-SSRS).\n15. Patients with stable prostate cancer may be included at the discretion of the Medical Monitor.\n16. Patients who are on monoclonal antibody medication for the treatment of Alzheimer's (ex. lecanemab, donanemab) for \\> 6 months or have discontinued monoclonal antibody medication for the treatment of Alzheimer's for \\> 6 months may be included if all other criteria has been met.\n\nExclusion Criteria:\n\n1. Taking one of the following medications: Medications for treatment of cancer or other drugs that weaken the immune system (ex. Natalizumab and Rituximab), Amiodarone, Bishydroxycoumarin, Chloramphenicol, Cimetidine, Fluconazole, Fluvastatin, Miconazole, Phenylbutazone, Sulphinpyrazone, Sulphadiazine, Sulphamethizole, Sulfamethoxazole, Sulphaphenazole, Trimethoprim, and Zafirlukast.\n2. Current active infection in participants including, but not limited to, herpes zoster, herpes infection, bronchitis, sinusitis, upper respiratory infection and fungal skin infection. Siponimod may increase the risk in participants with active infections.\n3. If participant received mRNA COVID-19 vaccination, must have received last dose at least 3 months prior to first dose of study drug\u002Fplacebo.\n4. Current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including (but not limited to) epilepsy, focal brain lesion, Parkinson's disease, seizure disorder, or head injury with loss of consciousness.\n5. Meets DSM IV criteria for any major psychiatric disorder including psychosis, major depression and bipolar disorder.\n6. Known history of or self-reported active alcohol and\u002F or substance abuse within the past three years.\n7. Isolated living circumstances which would prohibit a study partner from providing sufficient and credible information about the participant.\n8. Poorly controlled hypertension\n9. Known Atrioventricular heart block, known heart block type I-III.\n10. History of myocardial infarction or signs or symptoms of unstable coronary artery disease within the last year (including revascularization procedure\u002Fangioplasty).\n11. Severe pulmonary disease (including chronic obstructive pulmonary disease) requiring more than 2 hospitalizations within the past year.\n12. Untreated obstructive sleep apnea.\n13. Any thyroid disease (unless euthyroid on treatment for at least 6 months prior to screening).\n14. Active neoplastic disease (except for skin tumors other than melanoma) within five years.\n15. Absolute lymphocytopenia of \\\u003C1,000\u002Fmm3, or a history of lymphocytopenia within the past two years.\n16. Absolute neutropenia of \\\u003C1,000\u002Fmm3, or a history of neutropenia within the past two years.\n17. History of\u002F or current thromboembolism (including deep venous thrombosis).\n18. Any clinically significant hepatic or renal disease (including presence of Hepatitis B or C surface antigen or an elevated transaminase levels of greater than 2x the upper limit of normal (ULN) or creatinine greater than 1.5 x upper limit of normal (ULN)).\n19. Clinically significant hematologic or coagulation disorder including any unexplained anemia, or a platelet count less than 100,000\u002FµL at screening.\n20. Use of any investigational drug within 30 days or within five half-lives of the investigational agent, whichever is longer.\n21. Unwilling or unable to undergo CT or MRI imaging.\n22. In the opinion of the investigator, participation would not be in the best interest of the subject.\n23. Subjects with CYP2C9\\*3\u002F\\*3 genotyping","50 Years",{"count":386,"type":21},105,[388],"PHASE2","Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.",[292,391,392,28],"Mild Alzheimer Disease","MCI With Increased Risk for Alzheimer Disease",[394,395,128,82,396,397,398],"Alzheimer's disease","Siponimod","Brain Imaging","Biomarkers","Immunomodulation","2026-03-02",{"date":401,"type":41},"2026-03-04",{"date":403,"type":41},"2025-08-26",{"date":405,"type":21},"2029-10",{"name":407,"class":48},"St. Joseph's Hospital and Medical Center, Phoenix",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":416,"targetDuration":418,"studyType":122,"phases":4,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":49},"100614811","depressive-symptoms-cognitive-impairment-and-outcomes-in-hospitalized-chronic-heart-failure-patients-100614811","NCT07284446","Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients","Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure","DSCI-CHF","Inclusion Criteria:\n\n* patient hospitalized primarily for CHF exacerbation;\n* clinically stable, able to provide informed consent;\n* do not have severe cognitive impairment that would preclude valid questionnaire administration.\n\nExclusion Criteria:\n\n* hospitalization for acute heart failure;\n* total length of hospital stay \\\u003C96 hours;\n* absence of transthoracic echocardiography (TTE) within the last 12 months and no TTE planned;\n* severe visual impairment preventing completion of the visual part of the Montreal Cognitive Assessment;\n* refusal to participate.",{"count":417,"type":21},300,"12 Months","The goal of this observational study is to learn about the prevalence of depressive symptoms and cognitive impairment and their association with worse outcomes in a cohort of hospitalized patients between the ages of 18 ang 85 years with chronic heart failure. The main question it aims to answer is:\n\n• Does the presence of depressive symptoms and cognitive impairment lead to worse outcomes in a cohort of hospitalized patients with chronic heart failure? Participants who are hospitalized due to exacerbation of chronic heart failure will answer survey questions to assess their cognitive function and depressive symptoms.",[421,28,422],"Congestive Heart Failure Chronic","Depressive Symptoms Mild to Moderate in Severity",[424,361,425,426,427],"Congestive Heart Failure","Long-term Outcomes","Mild Depressive Symptoms","Rehospitalizations","2025-12-02",{"date":430,"type":41},"2025-12-16",{"date":428,"type":41},{"date":433,"type":21},"2028-12-02",{"name":435,"class":48},"Lithuanian University of Health Sciences",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":17,"minAge":285,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":49},"100589521","enact-program-on-auditory-perception-and-function-cognitive-function-and-health-related-quality-of-life-100589521","NCT06955494","ENACT Program on Auditory Perception and Function, Cognitive Function and Health-related Quality of Life","The Effect of the \"Empowerment Network for Auditory-Cognitive Training (ENACT) Program\" on Auditory Perception and Function, Cognitive Function and Health-related Quality of Life of Persons Living With Mild Cognitive Impairment","Inclusion Criteria:\n\n* Mild cognitive impairment accordingly to the Petersen's criteria\n* With at least one-side hearing impairment as defined by a score of 2- or 3- digit test greater than the norm value on the integrated Digit-in-Noise (iDIN test)\n* Has a smartphone to access the online training materials\n* Not received formal cognitive and auditory training in the past 6 months.\n* Available of primary caregiver in the family\n* give consent to participate\n\nExclusion Criteria:\n\n* moderate and severe cognitive impairment\n* Other sensory impairment",{"count":444,"type":21},62,[24],"Although previous studies indicated that tackling hearing loss may have a secondary benefit in improving cognitive function and delaying the onset of dementia, a more integrated care approach to optimize both hearing and cognitive function may be needed for individuals who already developed cognitive decline. To address the dual care needs for PwMCI and hearing impairment, it may be possible to integrate auditory training into cognitive training, as both of them are activity-based and focus on increasing the attention and working memory of an individual to engage in the auditory communication process. Moreover, auditory instruction is one of the core mediums in delivering cognitive training activities. It is highly possible to integrate the auditory training curricular to the corresponding administration process. To tackle the enhanced support need of individuals with dual functional impairment to engage in an integrated training protocol, strategies including a goal-oriented approach and peer support can be integrated to optimize the empowerment network. Including family members in the training is also important, as the auditory-communication process in everyday life would take place in the social interactional context.\n\nThis is a pilot mixed-method pilot study comprising a randomized controlled trial and a post-trail qualitative interview. A total of 62 participants will be recruited from two community centers. The inclusion criteria include mild cognitive impairment according to Petersen's criteria; with at least one-side hearing impairment as defined by a score of 2- or 3-digit test greater than the norm value on the integrated Digit-in-Noise (iDIN test); has a smartphone to access the online training materials; not received formal cognitive and auditory training in the past 6 months. After the baseline outcome evaluation, they will be randomized to receive the 12-week ENACT program or the usual care control. The nurse-led ENACT program comprises three phases, including i) the goal-oriented health counselling phase, ii) the peer-assisted group-based auditory-cognitive training phase, and iii) the family-engaged active-communication training phase. The outcome evaluation on hearing function, perceived benefit of auditory training, cognitive function, and HRQoL will be assessed at baseline, in the 12th and 18th weeks. Qualitative interviews will be conducted",[448,28],"Hearing Loss",[213,450],"hearing loss","2025-11-25",{"date":453,"type":41},"2025-12-03",{"date":455,"type":41},"2025-06-04",{"date":164,"type":21},{"name":344,"class":48},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":235,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":49},"100484896","early-phase-1-pharmacological-modulation-of-brain-oscillations-in-memory-processing-100484896","NCT05594017","Pharmacological Modulation of Brain Oscillations in Memory Processing","Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe","Patient inclusion criteria:\n\n1. Age 18 - 55 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n5. Body mass index between 18-35 kg\u002Fm2.\n\nPatient exclusion criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. Note that pregnant patients are excluded from undergoing iEEG generally and all patients undergo a positive screening urine test for drugs of abuse at screening: cannabinoids, cocaine, amphetamines, barbiturates, opiates not otherwise explained by their prescribed medications.\n3. History of renal insufficiency.\n4. Unstable cardiac syndrome or active cardiac symptoms.\n5. Patients with liver failure.\n6. Patients with BPH.\n7. Patients with autoimmune neuropathy.\n8. Patients with uncontrolled hyperthyroidism.\n9. Patients with a history of dementia.\n10. Patient with a history of delirium after using transdermal scopolamine.\n11. History of narrow-angle glaucoma.\n12. History of pyloric obstruction or paralytic ileus.\n13. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis.",{"count":177,"type":21},[258],"The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and\u002For spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.",[261,262,28,469,264],"Memory Disorders",[471,472,473],"oscillatory changes","cholinergic antagonist","muscarinic antagonist","2025-09-29",{"date":476,"type":41},"2025-10-03",{"date":478,"type":41},"2019-08-01",{"date":480,"type":21},"2027-05-31",{"name":277,"class":48},{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":57,"sex":17,"minAge":384,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":492,"briefSummary":493,"conditions":494,"keywords":498,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":4},"100529688","phase-2-mclena-2-a-phase-ii-clinical-trial-for-the-assessment-of-lenalidomide-in-patients-with-mild-cognitive-impairment-100529688","NCT06177028","MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment","MCLENA-2: A Phase II Clinical Trial for the Assessment of Biomarker Trajectory in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Treated With Lenalidomide (Amendment to IND # 142121)","In order to be eligible for this study, subjects must meet the following inclusion criteria:\n\nInclusion Criteria:\n\n1. Male or female outpatients.\n2. At least 50 years of age, but less than 90 (89 at time of screening)\n3. Females must be surgically sterile (bilateral tubal ligation, oophorectomy, or hysterectomy) or postmenopausal for 2 years (no women at risk of pregnancy will be accepted in this study).\n4. Must have been diagnosed with amnestic MCI based on the most recent NIA-AA criteria (Albert et al., 2011), i.e. at both the screening and baseline visits (visits 1 and 2) have a documented Mini Mental State Exam (MMSE) score between 22-28.\n5. CT or MRI scan of the brain obtained during the course of the dementia must be consistent with the diagnosis and show no evidence of significant focal lesions or of pathology which could contribute to dementia. If neither a CT nor an MRI scan is available from the past 12 months, a CT scan fulfilling the requirements must be obtained before randomization.\n6. Vision and hearing must be sufficient to comply with study procedures.\n7. Be able to take oral medications.\n8. Hachinski ischemic score must be ≤ 4.\n9. Geriatric depression scale must be ≤ 10.\n10. Can be on stable doses of a cholinesterase inhibitor and\u002For memantine as long as it is stable for at least 90 days before screening and is expected to remain on a stable dose for the remainder of the study period; or have demonstrated intolerance to or lack of efficacy from these medications.\n11. Must have a collateral informant\u002Fstudy partner who has significant direct contact with the patient at least 10 hours per week and who is willing to accompany the patient to specified clinic visits, supervise administration of all study medication, and be available for telephone visits\u002Finterviews.\n12. If the patient has a legally authorized representative (LAR), the LAR must review and sign the informed consent form. If the patient does not have an LAR, the patient must appear able to provide informed consent and must review and sign the informed consent form. In addition, the patient's informant\u002Fstudy partner (as defined above) must sign an informed consent form. If the LAR and the patient's informant \u002Fstudy partner is the same individual, he\u002Fshe should sign under both designations.\n13. Must reside in the community.\n14. Patients with stable prostate cancer may be included at the discretion of the Medical Monitor.\n15. Positivity for amyloid brain scan: Amyloid PET positive at SUVr of 1.05\n\nExclusion Criteria:\n\nSubjects will be excluded if they have any of the condition listed below:\n\n1. Current evidence or history within the last 3 years of a neurological or psychiatric illness that could contribute to dementia, including (but not limited to) epilepsy, focal brain lesion, Parkinson's disease, seizure disorder, head injury with loss of consciousness\n2. DSM IV criteria for any major psychiatric disorder including psychosis, major depression and bipolar disorder.\n3. Unwilling or unable to undergo a Lumbar Puncture.\n4. Known history or self-reported alcohol or substance abuse.\n5. Living alone.\n6. Poorly controlled hypertension. 7 .History of myocardial infarction or signs or symptoms of unstable coronary artery disease within the last year (including revascularization procedure\u002Fangioplasty).\n\n8\\. Severe pulmonary disease (including chronic obstructive pulmonary disease) requiring more than 2 hospitalizations within the past year.\n\n9\\. Untreated sleep apnea. 10. Any thyroid disease (unless euthyroid on treatment for at least 6 months prior to screening).\n\n11\\. Active neoplastic disease (except for skin tumors other than melanoma) within five years.\n\n12\\. History of multiple myeloma. 13. Absolute neutropenia of \\\u003C750\u002Fmm3, or a history of neutropenia. 14. History of or current thromboembolism (including deep venous thrombosis). 15. Any clinically significant hepatic or renal disease (including presence of Hepatitis B or C antigen\u002Fantibody or an elevated transaminase levels of greater than two times the upper limit of normal (ULN) or creatinine greater than 1.5 x ULN).\n\n16\\. Clinically significant hematologic or coagulation disorder including any unexplained anemia or a platelet count less than 100,000\u002FμL at screening.\n\n17\\. Use of any investigational drug within 30 days or within five half-lives of the investigational agent, whichever is longer.\n\n18\\. Use any investigational medical device within two weeks before screening or after end of the present study.\n\n19\\. Females who are at risk of pregnancy or are of child bearing age. 20. Unwilling or unable to undergo MRI and PET imaging. 21. Cardiac pacemaker or defibrillator or other implanted device. 22. In the opinion of the investigator, participation would not be in the best interest of the subject","90 Years",{"count":491,"type":21},45,[388],"This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as to changes in the relationship between the subject and study partner that might occur with the initiation of treatment and expectation of improvement in motor symptoms or cognition. Changes in subject\u002Fstudy partner interactions can impact subject mood and might introduce biases that cannot be quantified. The double-blind use of placebo will also prevent bias in the clinical and scientific assessments.",[28,84,495,496,497],"Amyloid Plaque","Neurodegenerative Disease, Hereditary","Inflammation, Brain",[394,499,397,396,500,264,398],"CSF","Brain Amyloid","2025-05-14",{"date":503,"type":41},"2025-05-18",{"date":505,"type":21},"2025-06-01",{"date":507,"type":21},"2027-01-02",{"name":407,"class":48}]